Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:CSII
CUSIP14161910
Phone651-259-1600
Debt
Debt-to-Equity Ratio0.16
Current Ratio4.47
Quick Ratio4.03
Price-To-Earnings
Trailing P/E Ratio727.80
Forward P/E Ratio-363.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$217.04 million
Price / Sales5.82
Cash Flow$0.1648 per share
Price / Cash220.82
Book Value$4.04 per share
Price / Book9.01
Profitability
EPS (Most Recent Fiscal Year)$0.05
Net Income$1.71 million
Net Margins0.79%
Return on Equity1.36%
Return on Assets0.88%
Miscellaneous
Employees652
Outstanding Shares34,710,000
Market Cap$1.30 billion
Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems Inc (NASDAQ:CSII) released its quarterly earnings data on Monday, July, 30th. The medical device company reported $0.11 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.06 by $0.05. The medical device company had revenue of $59.15 million for the quarter, compared to analysts' expectations of $58.43 million. Cardiovascular Systems had a net margin of 0.79% and a return on equity of 1.36%. View Cardiovascular Systems' Earnings History.
When is Cardiovascular Systems' next earnings date?
What price target have analysts set for CSII?
7 equities research analysts have issued twelve-month price objectives for Cardiovascular Systems' shares. Their forecasts range from $23.00 to $50.00. On average, they expect Cardiovascular Systems' share price to reach $37.00 in the next twelve months. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for Cardiovascular Systems.
What is the consensus analysts' recommendation for Cardiovascular Systems?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiovascular Systems.
What are Wall Street analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Over the recent times, Cardiovascular Systems has been facing cut-throat competition in the niche space. Further, its failure to successfully enter international markets and manage business might negatively affect the company’s financial results. On a positive note, the company witnessed year-over-year improvement in both Coronary device and peripheral device segments in the last reported quarter. Cardiovascular Systems is putting efforts in product innovation through R&D investments. Further, management seems to be upbeat about the exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral orbital atherectomy systems outside the United States and Japan. The market is also looking forward to the newly-launched coronary device in Japan, reflecting the company’s focus on international expansion. Overall, over the past six months, Cardiovascular Systems has outperformed its industry." (9/12/2018)
- 2. Needham & Company LLC analysts commented, "CSII’s F3Q18 revenue met consensus while EPS beat consensus. Management’s F4Q18 revenue guidance bracketed consensus while EPS guidance was above consensus. The F4Q18 revenue guidance requires a substantial acceleration from F3Q18 but we note that CSII faces a significantly easier revenue growth comp in F4Q18 than in F3Q18 (9.2% vs. 17.3%). Looking into FY19, CSII should continue to benefit from the Japanese launch, new support products, building rep productivity, and a further easing of comps so we think it can see its revenue growth accelerate further. However, it remains to be seen if CSII can sustain double- digit revenue growth and considering its 3.0x 2018E EV/sales multiple, we maintain our Hold rating." (5/3/2018)
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include Penumbra (PEN), Novocure (NVCR), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Atrion (ATRI), Luminex (LMNX), Tactile Systems Technology (TCMD), Cryolife (CRY) and K2M Group (KTWO).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, CEO & Pres (Age 58)
- Mr. Laurence L. Betterley, VP of Admin. (Age 64)
- Ms. Laura J. Gillund, Chief Talent Officer (Age 57)
- Mr. Jeffrey S. Points, Chief Financial Officer (Age 41)
- Ms. Rhonda J. Robb, Chief Operating Officer (Age 50)
Who are Cardiovascular Systems' major shareholders?
Cardiovascular Systems' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.17%), Strs Ohio (0.05%) and Versant Capital Management Inc (0.01%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Edward M Brown, Jeffrey S Points, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Sandra Sedo and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Which institutional investors are buying Cardiovascular Systems stock?
How do I buy shares of Cardiovascular Systems?
Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of CSII stock can currently be purchased for approximately $36.39.
How big of a company is Cardiovascular Systems?
Cardiovascular Systems has a market capitalization of $1.30 billion and generates $217.04 million in revenue each year. The medical device company earns $1.71 million in net income (profit) each year or $0.05 on an earnings per share basis. Cardiovascular Systems employs 652 workers across the globe.
What is Cardiovascular Systems' official website?
How can I contact Cardiovascular Systems?
Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
